Seeking Alpha

csymalla

csymalla
Send Message
View as an RSS Feed
View csymalla's Comments BY TICKER:
Latest  |  Highest rated
  • Cyclacel's sapacitabine unlikely to achieve efficacy endpoint in Phase 3 AML trial [View news story]
    please see comment here.
    http://bit.ly/1vWgeq9
    Dec 16, 2014. 01:11 PM | Likes Like |Link to Comment
  • Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis [View article]
    "Of 247 deaths in SEAMLESS, 173 (70%) have occurred in the first 6 months. This means that the survival curves beyond 6 months are poorly estimated at this time. Furthermore, follow up of European patients is significantly shorter than that of US patients due to the fact that the study opened for European accrual in April 2014. It is important to have complete follow up of all patients to ensure that a potential treatment effect beyond 6 months is not missed."

    hummmmmmmmmmm, what is the likely hood that survival rate will show significance after 6 months? The phase 1 results only had 35% death rate at 6 month mark. At the year mark 65% of patients died.

    It is interesting the experience is so different between phase 1 and 2. I'm not certain the survival rates of traditional chemo are between 6 months and 12, but phase 1 between 1 & 6 and 6 & 12 months the death rate was rather steady rather than stacked in the first 6 months.

    Anyone have any insight into this?
    Dec 16, 2014. 01:10 PM | Likes Like |Link to Comment
  • The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT) [View article]
    and what exactly would stop a company from creating a new line after patents expire? creating or more likely buying a cell line will become as easy as signing a check one day. To assume nobody can do what OCAT is doing in pepertuity is just folly.
    Dec 15, 2014. 10:24 AM | Likes Like |Link to Comment
  • The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT) [View article]
    Bio, it is way over reaching to give anything but the wildest hope to a Trillion $ valuation. Not only can reimbursement issues cause headwinds, but it would need other therapies than blood and eyes. There is no reason to not believe that generics won't enter the market after patent protections expire, which also means new therapies need to be developed. There is too much that needs to go right just to get the eye therapies to market, let alone wild speculation on absurd valuations a decade or two down the roads.
    Dec 8, 2014. 04:44 PM | 2 Likes Like |Link to Comment
  • The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT) [View article]
    Doug I'll give you mucho credit. you are a professional, chasing facts, logic and intelligent duscussion. We could all be a bit more like you.
    Dec 8, 2014. 12:39 PM | Likes Like |Link to Comment
  • The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT) [View article]
    That would be good Doug. Another topic that would be interesting would be about what to watch for on phase 2 design. IE: end points and possible headwinds and tailwinds as a result of design. I missed the quarter update where some of the phase 2 design may have been discussed.
    Dec 8, 2014. 12:23 PM | 1 Like Like |Link to Comment
  • The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT) [View article]
    omg, what is wrong with people? I expect your arrogance to improve with your next post too. lol
    Dec 8, 2014. 12:14 PM | 3 Likes Like |Link to Comment
  • The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT) [View article]
    I see you have the Cliff Clavin syndrom. Please enlighten us on chaos theory.
    Dec 8, 2014. 11:22 AM | 3 Likes Like |Link to Comment
  • The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT) [View article]
    Doug, the anology is that the company has moved from phase one to phase two. That coupled with moving to NASDAQ puts this company in position to be in a completely different phase than it has ever been in its life cycle. Depending how the science looks in phase two the public image and dilution don't necessarily offer the same level of tailwinds as they are at prior stage of development.
    Dec 8, 2014. 11:19 AM | 2 Likes Like |Link to Comment
  • The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT) [View article]
    sigh, when can we americans just get over critiquing and nitpicking each other to death. Well written article and I applaude the use of analogy and unique perspective, but not the overtly retentiveness of critiquing the use of "Butterfly Effect"
    Dec 8, 2014. 10:30 AM | 5 Likes Like |Link to Comment
  • Wall Street Breakfast: Apple Heads To Trial Over iTunes Update [View article]
    WSJ reported cyber monday was up 14 %
    Dec 2, 2014. 09:11 AM | 1 Like Like |Link to Comment
  • Advanced Cell Technology: All Systems Go [View article]
    You are exactly right Brooklyn. I would go a step futher. The classification is not a requirement to get the treatment approved in the EU. It is just a voluntary classification that clarifies the treatment is different than molecule based treatment. It is largely inconsequential other than defining Ocata's treatment as cellular based versus a typical molecule type drug.
    Nov 26, 2014. 11:03 AM | Likes Like |Link to Comment
  • Gilead buys FDA voucher for $125M [View news story]
    They didn't give it up. They sold it for cash. Think of it this way. What is better? Trying to convince investors to sink money in a money losing proposition or the FDA produces a product that they can sell for cash. It is a win win. They get money to develop a drug for disease that nobody else will touch and a company like Gilded gets a shorter review, which you can bet they will use on their most promising drug. That in turn gets it to market sooner.

    Arguments that FDA should provide that level of service to all other companies naturally are somewhat valid, but that becomes an issue of funding them so they have the resources to expedite review with the same level of scrutiny towards safety and effectiveness.
    Nov 20, 2014. 11:19 AM | 1 Like Like |Link to Comment
  • Gilead buys FDA voucher for $125M [View news story]
    I think everyone is missing the boat. the voucher is given to companies researching tropical diseases that big pharma will not touch due to economics. The idea is to have those companies sell the voucher to provide funding to bring these tropical disease drugs to market. It is all about funding for disease that does not make sense from a for profit standpoint.
    Nov 20, 2014. 10:12 AM | Likes Like |Link to Comment
  • Advanced Cell Technology: All Systems Go [View article]
    I have to admit, I was completely surprised when the publication came out and there was not even a modest pop.

    From the volume that traded the next few days it is evident there were many holders who were waiting for that binary event to make a quick profit.

    From my standpoint anyone who was thinking to make millions of $ off of phase 1 was just a dreamer anyway and had completely irrational expectations.

    I don't think that many are jumping in the stock to trade the up list binary event, which then means when the uplift happens buyers ought to outweigh the sellers. Good odds of getting a pop. This is just the start of where this gets interesting.
    Nov 13, 2014. 07:32 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
169 Comments
167 Likes